The complex challenge of delivering RNA-based therapeutics to treat serious diseases just received a financial boost, as Thalia Therapeutics Plc announced it has secured $3.6M in new funding.
The biotechnology company is dedicated to developing innovative RNA-based treatments and advanced delivery technologies, with a specific focus on oncology and cardiovascular disease. Thalia's mission is to overcome the fundamental hurdles of RNA delivery, enabling the creation of targeted, scalable, and clinically meaningful medicines for patients facing significant unmet medical needs.
